Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/27/20
Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-DestabilizerGlobeNewsWire • 02/10/20
Options Traders Expect Huge Moves in Arbutus Biopharma (ABUS) StockZacks Investment Research • 12/30/19
Arbutus Biopharma Corporation's (ABUS) CEO Bill Collier on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19
Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis BGlobeNewsWire • 10/03/19
Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of DirectorsGlobeNewsWire • 08/20/19
Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/05/19
Arbutus Biopharma Corporation (ABUS) CEO Mark Murray on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/07/19
Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/25/19